Home › Bile Duct Cancer (Cholangiocarcinoma) › Texas › Dallas
Bile Duct Cancer (Cholangiocarcinoma) clinical trials in Dallas, TX
5 studies for Bile Duct Cancer (Cholangiocarcinoma) are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
- University of Texas Southwestern Medical Center (Site 104), Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Baylor Scott & White Research Institute, Dallas
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
RecruitingPhase 1
- NEXT Dallas, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Dallas
Bile Duct Cancer (Cholangiocarcinoma) trials in other cities
- Houston, TX13 studies
- New York City, NY11 studies
- Boston, MA8 studies
- Rochester, MN7 studies
- Arlington, VA7 studies
- Los Angeles, CA7 studies
- Chicago, IL7 studies
- Columbus, OH6 studies
- Cleveland, OH6 studies
- Edison, NJ5 studies
- Queens, NY5 studies
- Nashville, TN5 studies
Other studies in Dallas
- Breast Cancer55 studies
- Non-Small Cell Lung Cancer52 studies
- Metastatic Cancer42 studies
- Heart Failure42 studies
- Cancer (all types)37 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity30 studies
- Ovarian Cancer28 studies
- Lung Cancer27 studies
- Bladder Cancer27 studies
- Endometrial Cancer24 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.